Literature DB >> 24999016

Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease.

Prue M Pereira-Fantini1, Susan Lapthorne2, Susan A Joyce3, Nicole L Dellios2, Guineva Wilson4, Fiona Fouhy5, Sarah L Thomas2, Michelle Scurr2, Colin Hill3, Cormac G M Gahan3, Paul D Cotter6, Peter J Fuller7, Winita Hardikar8, Julie E Bines9.   

Abstract

BACKGROUND & AIMS: Despite the mortality associated with liver disease observed in patients with short bowel syndrome (SBS), mechanisms underlying the development of SBS-associated liver disease (SBS-ALD) are poorly understood. This study examines the impact of bacterially-mediated bile acid (BA) dysmetabolism on farnesoid X receptor (FXR) signalling pathways and clinical outcome in a piglet model of SBS-ALD.
METHODS: 4-week old piglets underwent 75% small bowel resection (SBR) or sham operation. Liver histology and hepatic inflammatory gene expression were examined. Abundance of BA biotransforming bacteria was determined and metabolomic studies detailed the alterations in BA composition of stool, portal serum and bile samples. Gene expression of intestinal and hepatic FXR target genes and small heterodimer partner (SHP) transrepression targets were assessed.
RESULTS: Histological evidence of SBS-ALD included liver bile duct proliferation, hepatocyte ballooning and fibrosis. Inflammatory gene expression was increased. Microbiota changes included a 10-fold decrease in Clostridium and a two-fold decrease in Bacteroides in SBS-ALD piglets. BA composition was altered and reflected a primary BA dominant composition. Intestinal and hepatic regulation of BA synthesis was characterised by a blunted intestinal FXR activation response and a failure of SHP to repress key hepatic targets.
CONCLUSIONS: We propose a pathological scenario in which microbial dysbiosis following SBR results in significant BA dysmetabolism and consequent outcomes including steatorrhoea, persistent diarrhoea and liver damage. Furthermore alterations in BA composition may have contributed to the observed disturbance in FXR-mediated signalling pathways. These findings provide an insight into the complex mechanisms mediating the development of liver disease in patients with SBS. Crown
Copyright © 2014. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bile acids and salts; Farnesoid X receptor NR1H4; Gut microbiota; Intestinal failure associated liver disease; Liver diseases; Short bowel syndrome

Mesh:

Substances:

Year:  2014        PMID: 24999016     DOI: 10.1016/j.jhep.2014.06.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  23 in total

1.  Metagenomic analysis of the human microbiome reveals the association between the abundance of gut bile salt hydrolases and host health.

Authors:  Baolei Jia; Dongbin Park; Yoonsoo Hahn; Che Ok Jeon
Journal:  Gut Microbes       Date:  2020-04-24

2.  Differential action of TGR5 agonists on GLP-2 secretion and promotion of intestinal adaptation in a piglet short bowel model.

Authors:  Sen Lin; Barbara Stoll; Jason Robinson; Jose J Pastor; Juan C Marini; Ignacio R Ipharraguerre; Bolette Hartmann; Jens J Holst; Stephanie Cruz; Patricio Lau; Oluyinka Olutoye; Zhengfeng Fang; Douglas G Burrin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-03-28       Impact factor: 4.052

3.  Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism.

Authors:  Eric K Kwong; Xiaojiaoyang Li; Phillip B Hylemon; Huiping Zhou
Journal:  Curr Pharmacol Rep       Date:  2017-06-20

4.  Liver steatosis induced by small bowel resection is prevented by oral vancomycin.

Authors:  Lauren K Barron; Christopher P Gayer; Anne Roberts; Jamie M Golden; Bola G Aladegbami; Jun Guo; Christopher R Erwin; Brad W Warner
Journal:  Surgery       Date:  2016-08-31       Impact factor: 3.982

5.  Use of a novel docosahexaenoic acid formulation vs control in a neonatal porcine model of short bowel syndrome leads to greater intestinal absorption and higher systemic levels of DHA.

Authors:  Camilia R Martin; Barbara Stoll; Joanne Cluette-Brown; Adesola C Akinkuotu; Oluyinka O Olutoye; Kathleen M Gura; Pratibha Singh; Munir M Zaman; Michael C Perillo; Mark Puder; Steven D Freedman; Doug Burrin
Journal:  Nutr Res       Date:  2017-02-04       Impact factor: 3.315

6.  Gut microbiome in liver pathophysiology and cholestatic liver disease.

Authors:  Shengmin Yan; Xiao-Ming Yin
Journal:  Liver Res       Date:  2021-08-08

7.  A novel maladaptive unfolded protein response as a mechanism for small bowel resection-induced liver injury.

Authors:  Allie E Steinberger; Maria E Tecos; Hannah M Phelps; Deborah C Rubin; Nicholas O Davidson; Jun Guo; Brad W Warner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2022-06-21       Impact factor: 4.871

8.  Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.

Authors:  Yun-Xia Chen; Li-Na Lai; Hui-Ying Zhang; Yang-Hui Bi; Li Meng; Xu-Jiong Li; Xiao-Xia Tian; Li-Min Wang; Yi-Min Fan; Zhong-Fu Zhao; De-Wu Han; Cheng Ji
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

Review 9.  Implications of microbiota and bile acid in liver injury and regeneration.

Authors:  Hui-Xin Liu; Ryan Keane; Lili Sheng; Yu-Jui Yvonne Wan
Journal:  J Hepatol       Date:  2015-08-07       Impact factor: 25.083

10.  Cholecystectomy and Liver Disease in Short Bowel Syndrome.

Authors:  Jon S Thompson; Rebecca A Weseman; Fedja A Rochling; Elizabeth Lyden; Wendy J Grant; Luciano M Vargas; Alan N Langnas; David F Mercer
Journal:  J Gastrointest Surg       Date:  2015-10-26       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.